Padmanee Sharma

Padmanee Sharma

UNVERIFIED PROFILE

Are you Padmanee Sharma?   Register this Author

Register author
Padmanee Sharma

Padmanee Sharma

Publications by authors named "Padmanee Sharma"

Are you Padmanee Sharma?   Register this Author

100Publications

4526Reads

14Profile Views

Dissecting the mechanisms of immune checkpoint therapy.

Nat Rev Immunol 2020 Feb;20(2):75-76

Department of Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41577-020-0275-8DOI Listing
February 2020

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.

Cancer Immunol Res 2019 Nov 29;7(11):1803-1812. Epub 2019 Aug 29.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0873DOI Listing
November 2019

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.

Cell 2019 Nov;179(5):1177-1190.e13

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center UTHealth, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2019.10.029DOI Listing
November 2019

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.

Proc Natl Acad Sci U S A 2019 Oct 14;116(44):22246-22251. Epub 2019 Oct 14.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1908079116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825284PMC
October 2019

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.

Cancer Immunol Res 2019 Sep 9;7(9):1390-1395. Epub 2019 Jul 9.

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0605DOI Listing
September 2019

Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States.

Immunity 2019 04 26;50(4):1084-1098.e10. Epub 2019 Mar 26.

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10747613193009
Publisher Site
http://dx.doi.org/10.1016/j.immuni.2019.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664799PMC
April 2019

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.

Clin Cancer Res 2019 02 27;25(4):1233-1238. Epub 2018 Jul 27.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348141PMC
February 2019

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

J Clin Oncol 2018 10 15;36(28):2836-2844. Epub 2018 Aug 15.

Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834PMC
October 2018

Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.

J Clin Invest 2018 08 30;128(9):3813-3818. Epub 2018 Jul 30.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
https://www.jci.org/articles/view/99760
Publisher Site
http://dx.doi.org/10.1172/JCI99760DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118570PMC
August 2018

The emerging role of immune checkpoint based approaches in AML and MDS.

Leuk Lymphoma 2018 04 6;59(4):790-802. Epub 2017 Jul 6.

a Department of Leukemia , The University of Texas M. D. Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2017.1344905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872841PMC
April 2018

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

A potential biomarker for anti-PD-1 immunotherapy.

Nat Med 2018 02;24(2):123-124

Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nm.4489
Publisher Site
http://dx.doi.org/10.1038/nm.4489DOI Listing
February 2018

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

J Clin Oncol 2017 Dec 5;35(34):3851-3858. Epub 2017 Jul 5.

Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Lionel D. Lewis, The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH; Martin H. Voss, Memorial Sloan Kettering Cancer Center, New York, NY; Padmanee Sharma, MD Anderson Cancer Center, University of Texas, Houston, TX; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Albiruni R. Abdul Razak, Princess Margaret Cancer Centre, Toronto, Ontario; Christian Kollmannsberger, British Columbia Cancer Agency, Vancouver, British Columbia; Daniel Y.C. Heng, Tom Baker Cancer Center, University of Calgary, Calgary; Jennifer Spratlin, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; M. Brent McHenry, Bristol-Myers Squibb, Princeton, NJ; and Asim Amin, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.72.1985
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.72.1985DOI Listing
December 2017

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

Adv Exp Med Biol 2017 ;995:73-95

Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-53156-4_4DOI Listing
September 2017

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Cell 2017 Sep 10;170(6):1120-1133.e17. Epub 2017 Aug 10.

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.07.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591072PMC
September 2017

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Clin Chem 2017 07 17;63(7):1190-1195. Epub 2017 May 17.

Professor, Internal Medicine, Leader, Melanoma/Renal Cell Disease Research Team, Associate Chief, Section of Medical Oncology, Yale University, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2016.267849DOI Listing
July 2017

Genetic biomarker for cancer immunotherapy.

Science 2017 07;357(6349):358

Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aao1894DOI Listing
July 2017

Effective combinatorial immunotherapy for castration-resistant prostate cancer.

Nature 2017 03 20;543(7647):728-732. Epub 2017 Mar 20.

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature21676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374023PMC
March 2017

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Cell 2017 02;168(4):707-723

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.01.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391692PMC
February 2017

From the Guest Editor: Immune Checkpoint Therapy as a Weapon Against Cancer.

Authors:
Padmanee Sharma

Cancer J 2016 Mar-Apr;22(2):67

From the Departments of Genitourinary Medical Oncology and Immunology, M. D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847147PMC
January 2017

Immune Checkpoint Therapy and the Search for Predictive Biomarkers.

Authors:
Padmanee Sharma

Cancer J 2016 Mar-Apr;22(2):68-72

From the Departments of Immunology and Genitourinary Medical Oncology, M. D. Anderson Cancer Center, Houston, TX.P.S.'s work was supported by the SU2C-CRI Dream Team Cancer Immunotherapy Grant, PCF Challenge Grant in Immunology, NCI/NIH 1-R01 CA1633793-01, and Cancer Prevention Research in Texas (grant RP120108).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847150PMC
January 2017

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Cell 2016 Oct 22;167(2):397-404.e9. Epub 2016 Sep 22.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088716PMC
http://dx.doi.org/10.1016/j.cell.2016.08.069DOI Listing
October 2016

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.

Proc Natl Acad Sci U S A 2016 10 3;113(42):11919-11924. Epub 2016 Oct 3.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1611421113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081579PMC
October 2016

Monitoring immune responses in the tumor microenvironment.

Curr Opin Immunol 2016 08 27;41:23-31. Epub 2016 May 27.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Unit 1374, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2016.05.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5257261PMC
August 2016

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.

J Immunother Cancer 2016 21;4:36. Epub 2016 Jun 21.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1374, 1155 Pressler Street, Houston, TX 77030-3721 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0139-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915058PMC
June 2016

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1803-13. Epub 2015 Sep 25.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central Hospital and University of Helsinki, Helsinki (P.B.); South West Wales Cancer Institute and Swansea University College of Medicine, Swansea (J.W.), and Royal Marsden Hospital, London (J.L.) - both in the United Kingdom; University Hospital Essen of University of Duisburg-Essen, Germany (T.C.G.); Chiba Cancer Center, Chiba (T.U.), and Niigata University, Niigata (Y.T.) - both in Japan; Hospital Sao Jose, Beneficencia Portuguesa de São Paulo, São Paulo (F.A.S.); British Columbia Cancer Agency, Vancouver, BC, Canada (C.K.); Bristol-Myers Squibb, Lawrenceville (J.S.S., I.M.W.) and Hopewell (L.-A.X.) - both in New Jersey; and M.D. Anderson Cancer Center, University of Texas, Houston (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487PMC
November 2015

Targeting the tumor niche to treat cancer.

Proc Natl Acad Sci U S A 2015 Oct 8;112(42):12907-8. Epub 2015 Oct 8.

Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1517389112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620886PMC
October 2015

The future of immune checkpoint therapy.

Science 2015 Apr;348(6230):56-61

Department of Immunology, M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aaa8172DOI Listing
April 2015

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Cell 2015 Apr;161(2):205-14

Department of Immunology, MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.03.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905674PMC
April 2015

Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Cancer Immunol Res 2014 Aug;2(8):714-9

Icahn School of Medicine at Mount Sinai, New York, New York

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0119DOI Listing
August 2014

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

Cancer Cell 2014 Jun 22;25(6):719-34. Epub 2014 May 22.

Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180632PMC
June 2014

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.

J Immunother Cancer 2014 14;2:14. Epub 2014 May 14.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2051-1426-2-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039332PMC
June 2014

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.

J Exp Med 2014 Apr 31;211(4):715-25. Epub 2014 Mar 31.

Department of Immunology and 2 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20130590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978270PMC
April 2014

CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.

Cancer Immunol Res 2014 Feb 19;2(2):167-76. Epub 2013 Nov 19.

Authors' Affiliations: IRCM (Institut de recherches cliniques de Montreal) and Department of Medicine, University of Montreal, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-13-0155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004958PMC
February 2014

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.

Cancer Immunol Res 2013 Oct 31;1(4):229-34. Epub 2013 Jul 31.

Authors' Affiliations: Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-13-0020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636341PMC
October 2013

Harnessing the power of the immune system to target cancer.

Annu Rev Med 2013 22;64:71-90. Epub 2012 Oct 22.

Department of Melanoma Medical Oncology, The Center for Cancer Immunology Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://www.annualreviews.org/doi/10.1146/annurev-med-112311-
Publisher Site
http://dx.doi.org/10.1146/annurev-med-112311-083918DOI Listing
July 2013